A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria

New England Journal of Medicine

Volumn 336, Issue 2, 1997, Pages 86-91

  Stoute, José A ^a   Slaoui, Moncef ^b   Heppner, D Gray ^a   Momin, Patricia ^b   Kester, Kent E ^a   Desmons, Pierre ^b   Wellde, Bruce T ^a   Garçon, Nathalie ^b   Krzych, Urszula ^a   Marchand, Martine ^b   Ballou, W Ripley ^a   Cohen, Joe D ^b  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

MALARIA VACCINE; PROTOZOAL PROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; MALARIA; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPOROZOITE;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; EPITOPES; FEMALE; HEPATITIS B SURFACE ANTIGENS; HUMANS; IMMUNOGLOBULIN G; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; PROTOZOAN PROTEINS; TREATMENT OUTCOME; VACCINES, SYNTHETIC;

EID: 0004170486     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199701093360202     Document Type: Article

References (33)

1. World Health Organization. Twelfth programme report of the UNDP/World Bank/WHO special programme for research and training in tropical diseases (TDR). Bull World Health Organ 1995;12:64-76.
2. Rieckmann KH, Carson PE, Beaudoin RL, Cassells JS, Sell KW. Sporozoite induced immunity in man against an Ethiopian strain of Plasmodium falciparum. Trans R Soc Trop Med Hyg 1974;68:258-9.
3. Nardin EH, Nussenzweig V, Nussenzweig RS, et al. Circumsporozoite proteins of human malaria parasites Plasmodium falciparum and Plasmodium vivax. J Exp Med 1982;156:20-30.
4. Sinnis P, Nussenzweig V. Preventing sporozoite invasion ot hepatocytes. In: Hoffman SL, ed. Malaria vaccine development: a multi-immune response approach. Washington, D.C.: ASM Press, 1996:15-33.
5. Nardin EH, Nussenzweig RS. T cell responses to pre-erythrocytic stages of malaria: role in protection and vaccine development against pre-erythrocytic stages. Annu Rev Immunol 1993;11:687-727.
6. Ballou WR. Progress in malaria vaccines. In: Cryz SJ Jr, ed. Vaccines and immunotherapy. Elmsford, N.Y.: Pergamon Press, 1991:373-80.
7. Gordon DM, McGovern TW, Krzych U, et al. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J Infect Dis 1995;171:1576-85.
8. Glenn GM, Rao M, Richards RL, Matyas GR, Alving CR. Murine IgG subclass antibodies to antigens incorporated in liposomes containing lipid A. Immunol Lett 1995;47:73-8.
9. Hollinger FB, Troisi CL, Pepe PE. Anti-HBs responses to vaccination with a human hepatitis B vaccine made by recombinant DNA technology in yeast. J Infect Dis 1986;153:156-9.
10. Wirtz RA, Ballou WR, Schneider I, et al. Plasmodium falciparum: immunogenicity of circumsporozoite protein constructs produced in Escherichia coli. Exp Parasitol 1987;63:166-72.
11. Sinigaglia F, Guttinger M, Kilgus J, et al. A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules. Nature 1988;336:778-80.
12. Blum-Tirouvanziam U, Servis C, Habluetzel A, et al. Localization of HLA-A2.1-restricted T cell epitopes in the circumsporozoite protein of Plasmodium falciparum. J Immunol 1995;154:3922-31.
13. Aidoo M, Lalvani A, Allsopp CE, et al. Identification of conserved antigenic components for a cytotoxic T lymphocyte-inducing vaccine against malaria. Lancet 1995;345:1003-7.
14. Hill AVS, Elvin J, Willis AC, et al. Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature 1992;360:434-9.
15. Chulay JD, Schneider I, Cosgriff TM, et al. Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum. Am J Trop Med Hyg 1986;35:66-8.
16. Ballou WR, Rothbard J, Wirtz RA, et al. Immunogenicity of synthetic peptides from circumsporozoite protein of Plasmodium falciparum. Science 1985;228:996-9.
17. Ballou WR, Hoffman SL, Sherwood JA, et al. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet 1987;1:1277-81.
18. Herrington DA, Clyde DF, Losonsky G, et al. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature 1987;328:257-9.
19. Ballou WR, Young JF, Cryz SJ, Sadoff JC. The development of molecular vaccines against malaria sporozoites. Adv Exp Med Biol 1989;251: 295-313.
20. Sherwood JA, Oster CN, Adoyo-Adoyo M, et al. Safety and immunogenicity of a Plasmodium falciparum sporozoite vaccine: boosting of anti-body response in a population with prior natural exposure to malaria. Trans R Soc Trop Med Hyg 1991;85:336-40.
21. Brown AE, Singharaj P, Webster HK, et al. Safety, immunogenicity and limited efficacy study of a recombinant Plasmodium falciparum circumsporozoite vaccine in Thai soldiers. Vaccine 1994;12:102-8.
22. Hoffman SL, Edelman R, Bryan JP, et al. Safety, immunogenicity, and efficacy of a malaria sporozoite vaccine administered with monophosphoryl lipid A, cell wall skeleton of mycobacteria, and squalane as adjuvant. Am J Trop Med Hyg 1994;51:603-12.
23. Rutgers T, Gordon D, Gathoye AM, et al. Hepatitis B surface antigen as carrier matrix for the repetitive epitope of the circumsporozoite protein of Plasmodium falciparum. Biotechnology 1988;6:1065-70.
24. Vreden SG, Verhave JP, Oettinger T, Sauerwein RW, Meuwissen JH. Phase I clinical trial of a recombinant malaria vaccine consisting of the circumsporozoite repeat region of Plasmodium falciparum coupled to hepatitis B surface antigen. Am J Trop Med Hyg 1991;45:533-8.
25. Egan JE, Hoffman SL, Haynes JD, et al. Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites. Am J Trop Med Hyg 1993;49:166-73.
26. Nussenzweig V, Nussenzweig RS. Rationale for the development of an engineered sporozoite malaria vaccine. Adv Immunol 1989;45:283-334.
27. Hollingdale MR, Nardin EH, Tharavanij S, Schwartz AL, Nussenzweig RS. Inhibition of entry of Plasmodium falciparum and P. vivax sporozoites into cultured cells: an in vitro assay of protective antibodies. J Immunol 1984;132:909-13.
28. Hoffman SL, Oster CN, Plowe CV, et al. Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications. Science 1987;237:639-42.
29. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991-1045.
30. Scheller LF, Azad AF. Maintenance of protective immunity against malaria by persistent hepatic parasites derived from irradiated sporozoites. Proc Natl Acad Sci U S A 1995;92:4066-8.
31. Di Rosa F, Matzinger P. Long-lasting CD8 T cell memory in the absence of CD4 T cells or B cells. J Exp Med 1996;183:2153-63.
32. Schofield L, Villaquiran J, Ferreira A, Schellekens H, Nussenzweig RS, Nussenzweig V. Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. Nature 1987;330:664-6.
33. Moreno A, Clavijo P, Edelman R, et al. CD4+ T cell clones obtained from Plasmodium falciparum sporozoite-immunized volunteers recognize polymorphic sequences of the circumsporozoite protein. J Immunol 1993; 151:489-99.